HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

8th Edition of World Congress on Infectious Diseases

June 09-11, 2025 | Rome, Italy

June 09 -11, 2025 | Rome, Italy
Infection 2024

Develop the overall diagnosis and treatment strategy of infectious disease epidemic and create a novel precise diagnosis and treatment model of cytokine storm

Speaker at Infectious Diseases Conferences - Huiyi Feng
Shenzhen Hospital of Southern Medical University, China
Title : Develop the overall diagnosis and treatment strategy of infectious disease epidemic and create a novel precise diagnosis and treatment model of cytokine storm


In recent years, there have been frequent outbreaks of infectious diseases such as SARS and COVID-19, which pose a significant threat to human life, health, and socio-economic development. Despite the lack of a specific medicine to combat virus infections, the medical community and governments worldwide must urgently address the challenges posed by the pandemic. Developing a comprehensive set of diagnosis and treatment strategies and create an innovative precise diagnosis and treatment model for infectious diseases is critical. Medical research shows that viral infections damage the body through cytokine storm. However, modern medicine struggles to identify the characteristic patterns of cytokine storm in different illnesses and/or patients due to its complexity. This results in blind cytokine therapy and imprecise diagnosis and treatment. The authors have independently researched and compared traditional Chinese medicine (TCM) and modern medicine for 28 years, revealing the scientific essence of TCM with modern medical theory, and discovered in 1996 that the pathogenesis of TCM syndromes results from the disequilibrium status of cytokine network, or cytokine storm, and established a new medical theory integrating TCM and Western medicine. We successfully identified overall abnormal changing patterns of cytokine storm in human diseases, recognizing that different TCM syndromes represent varying patterns of disequilibrium status of cytokine storm. Based on the original cognition, the authors propose a new medical theory for formulating an overall diagnosis and treatment strategy and precision therapeutic regimen for infectious diseases or patients with infectious disease through evaluating the clinical manifestations of patients, which mean that medical communities and governments can develop a scientific approach to diagnose and treat epidemics  through only distinguishing clinical manifestations of a disease and clinicians can accurately diagnose and improve the effectiveness of treatments by judging the characteristics of cytokine storm through distinguishing clinical manifestations of the patient alone. In 2019, COVID-19 emerged, and the authors proposed that its pathogenesis was attributed to cytokine storm caused by the increased activity of transforming growth factor-b (TGF-b). The achievement was reported in Chinese media in February 2020 and later published in Frontiers in Public Health in May 2021, praised as a groundbreaking solution for medical diagnosis and treatment. Through careful theory research, the authors discovered some drugs and methods that inhibit TGF-b activity, leading to a breakthrough treatment for COVID-19, and miraculous efficacy was achieved in the patients with Covid-19 and its complications. So the authors declare here that we find specific medicine for the precise pathophysiological treatment of Covid-19 and the findings are significant for the current treatment of Covid-19 and precisely responding to future outbreaks. Regardless of future outbreaks of what major infectious diseases worldwide, the advancements can play a crucial role in scientific response, precise diagnosis, and treatment. Regrettably, the current medical community in China has yet to fully comprehend the scientific significance of this medical theory and its immense value in the diagnosis and treatment of diseases. As a result, it remains largely underutilized in clinical settings. We are eager to collaborate with forward-thinking scholars from all over the globe to undertake this vital research.


Dr. Feng has been engaged in clinical research on malignant tumors since 2009. Her major achievements include a randomized prospective cohort study on the prophylactic use of antiviral drugs in HBV carriers during chemotherapy, as well as a study on the high-risk factors of local recurrence after breast-conserving surgery in HER-2 positive breast cancer. Dr. Feng received her Ph.D. degree in 2018 with a focus on tumor biology and drug development. In 2019, Dr. Feng was appointed as the Vice-Chairman of the Clinical Oncology Nutrition and Metabolism Branch of the Shenzhen Anti-Cancer Association.